Gynecol Oncol. 2010 Jan 12
Research Conclusion: Our meta-analysis provides substantial evidence that bisphosphonates in the adjuvant setting among women with breast cancer do not decrease the number of fractures compared with placebo or no treatment. (Read the article)
My Two Cents: This is not surprising news, if you consider how bisphosphonates work (Fosomax, Actonel, Boniva, Didronel and Reclast). They inhibit osteoclasts, the cells that break down old, diseased and weak bone, from doing their job.
They also stimulate osteoblasts, cells responsible for depositing minerals into the holes created by the osteoclasts. If old bone is not broken down and discarded, it is left in place. This is what makes bisphonates look like they work to strengthen bone. In actuality, they keep bone from breaking down, but do not contribute to strength. Bone looks more solid on scans, but is not stronger. So, it makes sense that bisphosphonates would not prevent fracture. The side effects are not worth the risk.
Lack of Evidence for Fracture Prevention in Early Breast Cancer Bisphosphonate Trials: A Meta-analysis
